Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
In patients with acute myocardial infarction undergoing emergent percutaneous coronary intervention, we investigated CYP2C19 gene variants by using Spartan RX DNA testing system, determined the dose of antiplatelet agents, and then examined the relation between on-clpidogrel platelet aggregation, the related biomarkers and the prognosis in those patients. We aimed for 150 patients as a prospective interventional study, and enrolled 108 patients as of April 2015. We plan to start data analysis after the measurement of the above-mentioned biomarkers is finished in all enrolled patients.
|